Currently out of the existing stock ratings of Matt O'brien, 784 are a BUY (83.4%), 153 are a HOLD (16.28%), 3 are a SELL (0.32%).

Matt O'brien

Work Performance Price Targets & Ratings Chart

Analyst Matt O'brien, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 63.8% that have a potential upside of 29.61% achieved within 185 days.

Matt O'brien’s has documented 1,890 price targets and ratings displayed on 62 stocks. The coverage is on Healthcare, Financial Services sectors.

Most recent stock forecast was given on ATRC, AtriCure at 27-Aug-2026.

Wall Street Analyst Matt O'brien

Analyst best performing recommendations are on RMED (RA MEDICAL SYSTEMS).
The best stock recommendation documented was for KRMD (REPRO MED SYSTEMS) at 1/25/2021. The price target of $4.5 was fulfilled within 1 day with a profit of $0.63 (12.28%) receiving and performance score of 122.81.

Average potential price target upside

of $192 (15.26%) on RMED (RA MEDICAL SYSTEMS).
of $72.53 (62.85%) on MOTS (MOTUS GI HOLDINGS).
of $44.91 (22.54%) on ABMD (ABIOMED).

ABMD ABIOMED ALGN Align Technology APEN Apollo Endosurgery APYX Apyx Medical ATEC Alphatec Holdings ATRC AtriCure AZYO Aziyo Biologics BAX Baxter International BSX Boston Scientific Corp CNMD CONMED COO The Cooper Companies Common Stock DXCM DexCom ELGX Endologix FNA Paragon 28 GKOS Glaukos Corp GMED Globus Medical HUMA Humacyte IART Integra LifeSciences Holdings ISRG Intuitive Surgical ITMR Itamar Medical Ltd KIDS Orthopediatrics Corp KRMD Repro Med Systems LIVN LivaNova PLC MDT Medtronic PLC MDXG MiMedx Group MIRO Miromatrix Medical MMSI Merit Medical Systems MOTS Motus GI Holdings NUVA NuVasive NVTR Nuvectra PODD Insulet RMED RA Medical Systems SGHT Sight Sciences SPNE SeaSpine Holdings Corp SRGA Surgalign Holdings STIM Neuronetics SYK Stryker TCMD Tactile Systems Technology TELA Tela Bio TFX Teleflex TNDM Tandem Diabetes Care UTRS Minerva Surgical VRAY ViewRay WMGI Wright Medical Group N.V XENT Intersect ENT XRAY Dentsply Sirona ZBH Zimmer Biomet Holdings ZYXI Zynex CVRX CVRx CUTR Cutera RCEL Avita Medical Ltd RMD ResMed PEN Penumbra STAA STAAR Surgical Company ITGR Integer Holdings Corp PRCT Procept Biorobotics Corp TMDX TransMedics Group OBIO Orchestra BioMed Holdings RWLK Rewalk Robotics Ltd SI Silvergate Capital SIBN Si-Bone INGN Inogen

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Pito Chickering (DEUTSCHE BANK)

Buy Since 18-Jun-2021

$388

$6.98 (1.83%)

$355

3 years 11 months ago
(02-Nov-2022)

2/5 (40%)

$14.49 (3.88%)

Please subscribe to see extended stock data

Cecilia Furlong

Sell Since 15-Jul-2022

$380

$-1.02 (-0.27%)

$235

3 years 11 months ago
(02-Nov-2022)

1/2 (50%)

$6.49 (1.74%)

Please subscribe to see extended stock data

Matt O'brien (PIPER SANDLER)

Buy Since 22-Feb-2018

$380

$-1.02 (-0.27%)

$350

3 years 11 months 1 days ago
(01-Nov-2022)

24/41 (58.54%)

$2.18 (0.58%)

138

Please subscribe to see extended stock data

Anthony Petrone (MIZUHO)

Buy Since 30-Jun-2021

$300

3 years 11 months 19 days ago
(13-Oct-2022)

1/3 (33.33%)

$57.23 (23.57%)

Please subscribe to see extended stock data

Mike Polark (WOLFE)

$330

$-47.78 (-12.65%)

4 years 5 months 26 days ago
(06-Apr-2022)

1/1 (100%)

$16.24 (5.18%)

209

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Matt O'brien most bullish on?

Potential upside of $114.61 has been obtained for SYK (STRYKER)

Which stock is Matt O'brien most reserved on?

Potential downside of -$29.34 has been obtained for ITGR (INTEGER HOLDINGS CORP)

What Year was the first public recommendation made by Matt O'brien?

On 2014